… receptor (EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung
cancers (… with gefitinib harbour activating mutations in the EGFR gene. Consequently, EGFR …

… lung cancer, ~25% of lung cancer cases are not attributable to tobacco use (3). The increase
in lung cancer … in the prevalence of non-small cell lung cancer (NSCLC). NSCLC is more …

Background Epidermal growth factor receptor (EGFR) mutations in lung carcinomas can make
the disease more responsive to the treatment with tyrosine kinase inhibitors. We aimed to …

… demonstrates that the mutation pattern of lung cancer in never smokers is distinct and
separate from that observed in lung cancer patients of smokers. EGFR mutations were more …

… Lung cancer is the leading cause of cancer mortality worldwide and is responsible for ∼1.3
million deaths per year [1, 2]. The lung cancer … gene mutation-positive lung cancers and TNM …

… factor receptor (EGFR) gene product is a receptor tyrosine … that mutations in EGFR predict
the response of lung cancers to … The mutations are associated with adenocarcinoma histology…

… is the most common subtype, represents the leading cause of cancer related-… mutation in
non-small-cell lung cancer. Alterations in Kirsten rat sarcoma, epidermal growth factor receptor, …

… Two oral anti-cancer drugs that inhibit EGFR, gefitinib (Iressa) and erlotinib (Tarceva), … lung
cancer, and mutations in EGFR have been discovered in association with some lung cancers. …

… , lung cancer is one of the most common cancers worldwide [1, 2], and the most frequent type
is non-small cell lung cancer … shown that mutations in the epidermal growth factor receptor (…

… Lung cancer remains the leading cause of cancerrelated deaths in the US, and although …
growth factor receptor mutations and gene amplification in non-small-cell lung cancer: …